SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-familial Hypercholesterolemia
Conditions
Non-familial Hypercholesterolemia, Mixed Hyperlipidemia
Trial Timeline
Jul 30, 2021 → May 23, 2023
NCT ID
NCT04885218About SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placebo
SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placebo is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Non-familial Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT04885218. Target conditions include Non-familial Hypercholesterolemia, Mixed Hyperlipidemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04885218 | Phase 3 | Completed |
Competing Products
1 competing product in Non-familial Hypercholesterolemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IBI306 + placebo + placebo + IBI306 | Innovent Biologics | Phase 3 | 76 |